LT3728252T - 4-azaindolo junginiai - Google Patents

4-azaindolo junginiai

Info

Publication number
LT3728252T
LT3728252T LTEPPCT/US2018/065908T LTUS2018065908T LT3728252T LT 3728252 T LT3728252 T LT 3728252T LT US2018065908 T LTUS2018065908 T LT US2018065908T LT 3728252 T LT3728252 T LT 3728252T
Authority
LT
Lithuania
Prior art keywords
azaindole compounds
azaindole
compounds
Prior art date
Application number
LTEPPCT/US2018/065908T
Other languages
English (en)
Inventor
Alaric J. Dyckman
Dharmpal S. Dodd
Christopher P. Mussari
Trevor C. Sherwood
Brian K. Whiteley
John L. Gilmore
Sreekantha Ratna KUMAR
Laxman PASUNOORI
Pitani Veera Venkata Srinivas
Srinivasan Kunchithapatham Duraisamy
Subramanya HEGDE
Rushith Kumar Anumula
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3728252T publication Critical patent/LT3728252T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEPPCT/US2018/065908T 2017-12-18 2018-12-17 4-azaindolo junginiai LT3728252T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762599875P 2017-12-18 2017-12-18
PCT/US2018/065908 WO2019125977A1 (en) 2017-12-18 2018-12-17 4-azaindole compounds

Publications (1)

Publication Number Publication Date
LT3728252T true LT3728252T (lt) 2023-10-25

Family

ID=65003548

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/065908T LT3728252T (lt) 2017-12-18 2018-12-17 4-azaindolo junginiai

Country Status (27)

Country Link
US (4) US10544143B2 (lt)
EP (1) EP3728252B1 (lt)
JP (1) JP7289301B2 (lt)
KR (1) KR20200100709A (lt)
CN (1) CN111819176B (lt)
AR (1) AR113959A1 (lt)
AU (1) AU2018388464B2 (lt)
BR (1) BR112020011771A2 (lt)
CA (1) CA3085817A1 (lt)
CL (1) CL2020001546A1 (lt)
DK (1) DK3728252T3 (lt)
EA (1) EA202091484A1 (lt)
ES (1) ES2960411T3 (lt)
FI (1) FI3728252T3 (lt)
HR (1) HRP20231244T1 (lt)
HU (1) HUE064473T2 (lt)
IL (1) IL275344B2 (lt)
LT (1) LT3728252T (lt)
MX (1) MX2020006168A (lt)
PE (1) PE20210129A1 (lt)
PL (1) PL3728252T3 (lt)
PT (1) PT3728252T (lt)
RS (1) RS64728B1 (lt)
SG (1) SG11202005628RA (lt)
SI (1) SI3728252T1 (lt)
TW (1) TWI689510B (lt)
WO (1) WO2019125977A1 (lt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
FI3728252T3 (fi) * 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä
ES2904676T3 (es) * 2017-12-20 2022-04-05 Bristol Myers Squibb Co Compuestos de amino indol útiles como inhibidores de TLR
CA3085942A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
CA3085937A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Diazaindole compounds
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ. ホフマン-ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
CN112313228A (zh) 2018-06-12 2021-02-02 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的新型杂芳基杂环基化合物
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
WO2020048583A1 (en) 2018-09-04 2020-03-12 F. Hoffmann-La Roche Ag Benzothiazole compounds for the treatment of autoimmune diseases
EP3847170B1 (en) 2018-09-06 2022-06-22 F. Hoffmann-La Roche AG Novel cyclic amidine compounds for the treatment of autoimmune disease
JP2022550203A (ja) * 2019-10-01 2022-11-30 ブリストル-マイヤーズ スクイブ カンパニー 置換二環ヘテロアリール化合物
KR20220097434A (ko) * 2019-11-01 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 톨 수용체 억제제로서의 치환된 피라졸 화합물
AR123284A1 (es) * 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9
CA3214808A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL340412A1 (en) 1997-10-20 2001-01-29 Hoffmann La Roche Bicyclic kinase inhibitors
CZ20012006A3 (cs) 1998-12-18 2002-03-13 Axys Pharmaceuticals, Inc. Sloučenina a farmaceutický prostředek
CA2528774A1 (en) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
CN1980934B (zh) 2004-05-03 2011-10-26 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的新的吲哚衍生物
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
AU2007234399A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
BRPI0915231A2 (pt) * 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
EP2350032B1 (en) 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
EP2364314B1 (en) 2008-12-09 2014-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
CA2768236C (en) 2009-07-16 2018-05-22 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
MX348935B (es) 2011-01-12 2017-07-03 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
JP6093759B2 (ja) 2011-06-01 2017-03-08 ジャナス バイオセラピューティクス,インク. 新規の免疫系調節剤
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
IN2014MN00258A (lt) 2011-07-15 2015-09-25 Janssen Pharmaceuticals Inc
JP2013075834A (ja) 2011-09-29 2013-04-25 Kowa Co Tlr9阻害活性を有するピラゾロピリミジン−7−アミン誘導体
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
ES2644702T3 (es) 2012-05-18 2017-11-30 Sumitomo Dainippon Pharma Co., Ltd. Compuestos de ácido carboxílico
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2738172A1 (en) * 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
CA2933466A1 (en) 2013-12-13 2015-06-18 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
SG11201701169XA (en) 2014-08-15 2017-03-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidine compounds used as tlr7 agonist
US20170275287A1 (en) 2014-08-22 2017-09-28 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
US11180474B2 (en) 2016-07-30 2021-11-23 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
FI3728252T3 (fi) * 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä

Also Published As

Publication number Publication date
MX2020006168A (es) 2020-08-13
KR20200100709A (ko) 2020-08-26
US10544143B2 (en) 2020-01-28
HRP20231244T1 (hr) 2024-02-16
FI3728252T3 (fi) 2023-10-18
JP2021506858A (ja) 2021-02-22
US20220340555A1 (en) 2022-10-27
EP3728252A1 (en) 2020-10-28
US20200095247A1 (en) 2020-03-26
US10730877B2 (en) 2020-08-04
BR112020011771A2 (pt) 2020-11-17
US11053244B1 (en) 2021-07-06
CN111819176A (zh) 2020-10-23
ES2960411T3 (es) 2024-03-04
JP7289301B2 (ja) 2023-06-09
IL275344A (en) 2020-07-30
EA202091484A1 (ru) 2021-03-25
CA3085817A1 (en) 2019-06-27
RS64728B1 (sr) 2023-11-30
DK3728252T3 (da) 2023-11-13
PT3728252T (pt) 2023-10-26
IL275344B1 (en) 2023-04-01
PL3728252T3 (pl) 2023-10-23
TW201927780A (zh) 2019-07-16
PE20210129A1 (es) 2021-01-19
US11820768B2 (en) 2023-11-21
CN111819176B (zh) 2023-12-15
EP3728252B1 (en) 2023-08-09
AR113959A1 (es) 2020-07-01
AU2018388464B2 (en) 2022-07-21
CL2020001546A1 (es) 2020-10-23
WO2019125977A1 (en) 2019-06-27
SG11202005628RA (en) 2020-07-29
SI3728252T1 (sl) 2023-11-30
HUE064473T2 (hu) 2024-03-28
US20190185469A1 (en) 2019-06-20
TWI689510B (zh) 2020-04-01
IL275344B2 (en) 2023-08-01
AU2018388464A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
IL275365A (en) 6-Azaindole compounds
IL275344A (en) 4-azaindole compounds
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201700814D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201716352D0 (en) Compounds
GB201716374D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201713318D0 (en) Compounds
GB201713319D0 (en) Compounds
GB201711982D0 (en) Compounds
GB201709642D0 (en) Compounds
GB201708845D0 (en) Compounds
GB201708846D0 (en) Compounds